Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/5325
Title: Novel agents targeting bioactive sphingolipids for the treatment of cancer
Authors: Adan Gökbulut, Aysun
Kartal Yandım, Melis
İskender, Güniz
Baran, Yusuf
Adan Gökbulut, Aysun
Kartal Yandım, Melis
İskender, Güniz
Baran, Yusuf
Keywords: Bioactive sphingolipids
Cancer
Ceramides
Drug resistance
Glucosylceramide synthase
Issue Date: Jan-2013
Publisher: Bentham Science Publishers B.V.
Source: Adan Gökbulut, A., Kartal Yandım, M., İskender, G., and Baran, Y. (2013). Novel agents targeting bioactive sphingolipids for the treatment of cancer. Current Medicinal Chemistry, 20(1), 108-122. doi:10.2174/09298673130111
Abstract: Sphingolipids are a class of lipids that have important functions in a variety of cellular processes such as, differentiation, proliferation, senescence, apoptosis and chemotherapeutic resistance. The most widely studied bioactive shingolipids include ceramides, dihydroceramide (dhCer), ceramide-1-phosphate (C1P), glucosyl-ceramide (GluCer), sphingosine and sphingosine-1-phosphate (S1P). Although the length of fatty acid chain affects the physiological role, ceramides and sphingosine are known to induce apoptosis whereas C1P, S1P and GluCer induce proliferation of cells, which causes the development of chemoresistance. Previous studies have implicated the significance of bioactive shingolipids in oncogenesis, cancer progression and drug- and radiation-resistance. Therefore, targeting the elements of sphingolipid metabolism appears important for the development of novel therapeutics or to increase the effectiveness of the current treatment strategies. Some approaches involve the development of synthetic ceramide analogs, small molecule inhibitors of enzymes such as sphingosine kinase, acid ceramidase or ceramide synthase that catalyze ceramide catabolism or its conversion to various molecular species and S1P receptor antagonists. These approaches mainly aim to up-regulate the levels of apoptotic shingolipids while the proliferative ones are down-regulated, or to directly deliver cytotoxic sphingolipids like short-chain ceramide analogs to tumor cells. It is suggested that a combination therapy with conventional cytotoxic approaches while preventing the conversion of ceramide to S1P and consequently increasing the ceramide levels would be more beneficial. This review compiles the current knowledge about sphingolipids, and mainly focuses on novel agents modulating sphingolipid pathways that represent recent therapeutic strategies for the treatment of cancer. © 2013 Bentham Science Publishers.
URI: http://doi.org/10.2174/09298673130111
http://hdl.handle.net/11147/5325
ISSN: 0929-8673
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File Description SizeFormat 
5325.pdfİnceleme (Review)366.47 kBAdobe PDFThumbnail
View/Open
Show full item record

CORE Recommender

SCOPUSTM   
Citations

39
checked on Oct 16, 2021

Page view(s)

18
checked on Oct 16, 2021

Download(s)

40
checked on Oct 16, 2021

Google ScholarTM

Check

Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.